Skip to main content

AffaMed Approved to Start China Trial of Parkinson's Candidate

Shanghai AffaMed Therapeutics was approved to start a China Phase IIb trial of its Parkinson's Disease candidate. AM006 is a novel non-ergot dopamine agonist that acts by stimulating striatal dopamine receptors. Because AM006 has a higher affinity for dopamine receptors, and more balanced activation of D2 and D3 receptors, it is expected to show fewer side effects than other members the dopamine agonist class. In  2020, AffaMed acquired Greater China rights to the candidate from Kissei Pharma, a Japanese company. AffaMed will join the global Phase IIb trial of the molecule. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.